drugset / Trial / NCT06231641
The Effects of Lemborexant on the Ability to Sleep During Daytime
Phase 2
Terminated
5 enrolled
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
RandomizedCrossoverDouble-blindTreatment
Summary
This study aim to evaluate whether a dose of 5 mg of lemborexant, as compared to a placebo, may improve daytime recovery sleep, without producing lingering sleepiness during wakefulness, using a 3-day simulated night shift protocol in the lab under constant monitoring.
Timeline
- Start
- 2024-01-11
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lemborexant | Small molecule | 5 mg | Oral |